Merit Medical to Host Luncheon Symposium on Dialysis Techniques at CIDA 2013

Merit Medical is looking forward to attending the 2013 Controversies in Dialysis Access (CIDA) Meeting October 24-25 at the Westin St. Francis in San Francisco, California. Merit Medical will be hosting a luncheon symposium:
Dialysis Techniques and Clinical Outcomes
Moderator:
Stephen R. Ash, MD, Interventional Nephrologist, Ash Access Technology, Inc.
Speakers:
Saravanan Balamuthsamy, MD, Angiocare, Tucson, AZ
90 Day Patency Comparison: Self-Centering, Split-Tip Catheter vs Symmetric-Tip Catheter
Peter Hathaway, MD, Utah Vascular Clinic, Salt Lake City, UT
Peritoneal Dialysis – Percutaneous Case and Technique
Thursday, October 24,
12:00 PM-1:00 PM
California West Room
Merit Medical will also be sponsoring a Live Peritoneal Dialysis Catheter Placement Procedure by John Ross, MD, RMC Dialysis Access Institute, Orangeburg, South Carolina.
We hope you will join us for both the Luncheon Symposium.
Click on the links below to learn more about Merit Medical’s catheters and accessories for long-term hemodialysis and peritoneal dialysis including CentrosFLO® and ProGuide™ long-term hemodialysis catheters.
Chan Ream

Product Manager

Merit Medical Launches Embosphere® and HepaSphereTM Microspheres in Japan

I am pleased to announce that Nippon Kayaku (authorized distributor for Merit Medical Systems, Inc.) has received distribution and marketing authorization in Japan for Embosphere Microspheres and HepaSphere Microspheres.
The Japan Ministry of Health, Labour and Welfare held the “10th Investigative Commission about Expedited Introduction of Medical Devices, Which Are Strongly Needed in Medical Treatment” and it recommended the introduction of Embosphere and HepaSphere Microspheres to the Japan market. The recommendation was fulfilled by approval of both products in June 2013.
Embosphere Microspheres, the most clinically studied round embolic, provide consistent and predictable results for effective embolization in the treatment of uterine fibroids, hypervascular tumors, and arteriovenous malformations. Used worldwide in over 250,000 procedures since 2002, Embosphere Microspheres are the gold standard in uterine fibroid embolization, with Interventional Radiologists choosing Embosphere Microspheres in 73% of cases according to the FIBROID registry published in Obstetrics and Gynecology.
HepaSphere Microspheres are biocompatible, hydrophilic, nonresorbable, and conformable microspheres designed for controlled, targeted embolization. HepaSphere Microspheres also rapidly absorb aqueous solutions such as contrast media or saline. HepaSphere Microspheres enable physicians to optimize outcomes by more precisely matching the sphere size to the size of the targeted vasculature. In Japan, HepaSphere Microspheres are indicated for use in embolization of blood vessels for therapeutic or preoperative purposes in the following procedures:

  • Embolization of hepatocellular carcinoma
  • Embolization of metastases to the liver
Please visit our product pages for more information.
Noah Wong
Product Manager, Merit Medical

You Have Options For Treating Your Uterine Fibroids

Did you know that there are minimally-invasive treatment options available to treat uterine fibroids and the common symptoms associated with them: heavy bleeding, pelvic pain, and frequent urination?
In 2008, Uterine Fibroid Embolization (UFE) was recognized by the American College of Obstetricians and Gynecologists (ACOG) as an alternative to hysterectomy in the management of uterine fibroids.
      If you are not a good candidate for hysterectomy,
      If you want to avoid surgery for your fibroids,
      If you want to keep your uterus,
ASK ABOUT UFE!
UFE is a proven, effective option for treating uterine fibroids. To learn more about your options, go to www.ask4ufe.com.

Merit Medical Announces the Latest in Inflation Device Technology– the New basixTOUCH™

Merit Medical’s 35 ATM basixTOUCH Inflation Device is now available in the U.S., Europe, and many other countries around the world. The basixTOUCH is the latest innovation in inflation from Merit, and offers 35 ATM pressure capability as well as 30 mL of syringe volume to make it easier to accommodate a wide array of interventional balloons.

We surveyed hundreds of physicians and techs, and found a strong desire for a device that was easy on the hands, quick to set up, easy to inflate, and fast to deflate. From this feedback, Merit has designed a device with one-handed prep, an easy-to-turn quick-release handle.

basixtouch

The basixTOUCH expands your capacity with the innovation, quality, and reliability that Merit customers have enjoyed for over 25 years. To learn more about this new product and other products supporting interventional and diagnostic procedures, please contact your local Merit Sales Representative or visit us at www.merit.com.

Guido Sandulli
Director of Marketing, Interventional Cardiology

First Commercial Cases with STAR System in Europe

DFINE ANNOUNCES FIRST COMMERCIAL CASES WITH STAR TUMOR ABLATION SYSTEM IN EUROPE

San Jose, Calif. – October 9, 2013 – DFINE, Inc., a fast-growing market leader in the treatment of spinal diseases, today announced the completion of the first European commercial cases with the STAR™ Tumor Ablation System for the palliative treatment of painful metastatic spinal tumors since the device received CE Mark approval last month.

The Targeted Radiofrequency Ablation (t-RFA) procedures using the STAR System were performed in Germany, Italy and the United Kingdom over the past two weeks.

According to Dr. Winston Rennie at the University of Leicester’s, Leicester Royal Infirmary who performed the first case in the UK, “t-RFA is one of the most innovative and exciting developments I have seen for the palliative treatment of painful spinal tumors in recent years,” he said. “The unique design of the STAR System allows me to deliver a very targeted and controlled ablation next to critical spinal structures, burn tumors and provide rapid pain relief in a single procedure. I was very pleased with the initial experience and can see a significant need for this in percutaneous cancer treatment and spine augmentation in the UK.”

The STAR System received 510k clearance in August 2010 and has demonstrated strong clinical outcomes in the U.S. and abroad. In September, the company announced the CE Mark approval and European product launch at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress.

“We are pleased with the very quick start in Europe and believe that it is indicative of the unmet clinical need for patients with painful spinal metastases,” said Greg Barrett, Chief Executive Officer of DFINE. “Our goal is to expand into centers across all European markets in an effort to make the therapy available to the many thousands of patients suffering from painful spinal tumors.”

About STAR™ Tumor Ablation System

t-RFA with the STAR System does not treat cancer. It is cleared by the FDA for providing palliative treatment (e.g. pain relief) by ablation of metastatic malignant tumors in a vertebral body. For a complete list of indications, risks and contraindications, visit http://www.dfineinc.com/Product-Risk—SpineSTAR

About DFINE, Inc.

DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies. The company’s flagship products, the StabiliT® Vertebral Augmentation System and STAR™ Tumor Ablation System, represent generational advancements in the minimally invasive treatment of spinal diseases. DFINE is based in San Jose, Calif. and is a privately held company. DFINE and StabiliT are registered trademarks and STAR and Targeted Radiofrequency Ablation (t-RFA) are trademarks of DFINE, Inc.

Merit Medical™ Endovascular Snare System Interactive iPad App Version 2.0 Now Available!

I am pleased to announce the availability of the Merit Medical Snare Interactive App version 2.0 for the iPad.

The app is designed to help you select the appropriate size EN Snare® or ONE Snare® to use in a desired vein or artery. The app is also designed to provide the technical product specifications for reference and ordering purposes.

DOWNLOAD the Merit Snare Interactive App for the iPad by clicking on the following link:
http://cloud.merit.com/apps/meritsnares/index.html

ADD THIS INTERACTIVE APP TO YOUR iPAD

  • Open the link in Safari
  • Select the menu option “Add to Home Screen ”
  • Once complete, close Safari
  • Access the app directly by tapping on the Merit Snares app icon

Merit Medical’s EN Snare and ONE Snare Endovascular Snares
Accuracy.Reliability.Options.

Jesse Hansen
Director of Marketing – Interventional Radiology